AP NEWS

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO and MGTI

October 10, 2018

NEW YORK, Oct. 10, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) Class Period: December 14, 2017 to August 7, 2018 Lead Plaintiff Deadline: October 24, 2018

According to the complaint, Ampio Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

Get additional information about the AMPE lawsuit: http://www.kleinstocklaw.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3

Nevro Corp. (NYSE: NVRO) Class Period: January 8, 2018 to July 12, 2018 Lead Plaintiff Deadline: October 22, 2018

The complaint alleges that during the class period Nevro Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company’s Senza I and Senza II systems; (2) as a result, Nevro’s Senza I and Senza II systems were not “novel” or “proprietary;” (3) these practices caused Nevro to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro’s U.S. sales growth was not sustainable; and (5) consequently, defendants’ statements about Nevro’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the NVRO lawsuit: http://www.kleinstocklaw.com/pslra-1/nevro-corp-loss-form?wire=3

MGT Capital Investments Inc. (OTCMKTS: MGTI) Class Period: October 9, 2015 to September 7, 2018 Lead Plaintiff Deadline: November 27, 2018

The complaint alleges MGT Capital Investments Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (2) this illicit scheme caused MGT Capital to make false and misleading statements, which would result in governmental scrutiny, including from the SEC; (3) certain of the defendants exercised control over MGT Capital and its management; (4) consequently, the illicit scheme would ultimately cause MGT Capital’s stock to become delisted from NYSE MKT; and (5) as a result, defendants’ statements about MGT Capital’s business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the MGTI lawsuit: http://www.kleinstocklaw.com/pslra-1/mgt-capital-investments-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Joseph Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com

AP RADIO
Update hourly